On the other hand, similar to ALK and ROS1 fusion-positive lung cancers, patients with NTRK fusion also can develop off-target resistance to TKI therapy, mechanisms including MET amplification, BRAF V600E mutation, or hotspot mutations involving KRAS [365]. This evidence concerns the gene ALK and lung carcinoma.